# MariTide Beginner's Guide: What Maridebart Cafraglutide Is
> Note: PeptIQ is not a medical provider. MariTide is investigational. Educational content only.
If weekly GLP-1 fatigue is the cultural complaint, MariTide is the monthly answer Amgen is testing. The drug name in papers is maridebart cafraglutide (formerly AMG 133) — a long-acting peptide-antibody conjugate for obesity (with and without type 2 diabetes).
What Makes MariTide Different
| Feature | Why beginners care |
|---|---|
| Monthly (or less frequent) SC dosing | Fewer injection days than weekly incretins |
| Peptide-antibody conjugate design | Long half-life engineering, not a simple weekly peptide copy |
| Strong Phase 2 weight-loss signal | Up to ~20% mean loss at 52 weeks in efficacy-style summaries (obesity without T2D) |
| Glycemic story in T2D cohort | Meaningful A1c reductions reported alongside weight loss |
How It Fits the 2026 Obesity Map
- Weekly dual/triple agonists: tirzepatide, retatrutide, survodutide, CT-388
- Amylin lane: eloralintide, cagrilintide / CagriSema, petrelintide, amycretin
- Oral GLP-1: orforglipron
- Monthly conjugate: MariTide
Beginners should learn pathway + cadence before chasing percent-loss leaderboards.
Phase 2 Snapshot (Beginner Version)
- Primary endpoint: percent weight change at 52 weeks
- Dose exploration around 140–420 mg every 4 weeks (+ less frequent / escalation arms)
- Weight loss had not clearly plateaued by week 52 in Amgen communications — a "more may come with longer treatment" signal
- GI side effects remain class-typical; escalation helped in public summaries
What to Track If You Follow Monthly Protocols
- Injection day on a monthly calendar
- Hunger / food noise / meal size
- GI scores for several days post-dose
- Protein + lifting (lean mass protection)
- Waist + 7-day average weight
- A1c / fasting glucose when relevant
FAQ
Q: Is MariTide FDA-approved?
A: Check current status with clinicians and regulators. Treat public Phase 2 data as research literacy until labeled.
Q: Can I buy MariTide as a research peptide?
A: Clinical trial product ≠ gray-market vials. Evidence tier and legality first.
Q: Is monthly always better than weekly?
A: Adherence can improve with fewer injections — but tolerability after a large monthly exposure is a different risk shape than weekly micro-steps.
Bottom Line
MariTide is the monthly obesity pipeline name to know in 2026: maridebart cafraglutide, Phase 2 double-digit weight loss, dose map in the hundreds of milligrams every 4 weeks. Start with cadence literacy, not DIY reconstitution charts.
Download PeptIQ to track long-interval metabolic protocols cleanly.
Educational content only. Not medical advice.
